Dyax in exclusive talks with Dompé over DX-88
This article was originally published in Scrip
Executive Summary
Dyax has entered into an exclusive negotiation period ending on September 30th with Italian firm Dompé Farmaceutici for a European licence to its kallikrein inhibitor